Selected Journal Citations

Research at Johns Hopkins
		News Releases
		Research Interests/ Programs of Faculty

The Johns Hopkins Ovarian Cancer Center of Excellence acknowledges and thanks Aventis, Genzyme, GlaxoSmithKline, Oncotech, Ortho Biotech, and The Pam McDonald Fund for their support of this website through provision of unrestricted educational grants.

The Johns Hopkins Ovarian Cancer Center of Excellence

Select Journal Citations

(listed alphabetically, scroll down for more faculty)

Deborah Armstrong, M.D.

Bristow RE, Tomacruz RS, Armstrong, DK, Trimble EL and Montz FJ. Survival impact of maximum cytoreductive surgery for advanced ovarian carcinoma during the platinum-era: a meta-analysis of 6,885 patients. J Clin Oncol 20:1248-59, 2002.

Alberts DS, Markman M, Armstrong D, Rothenberg M, Muggia F and Howell SB. Intraperitoneal Therapy for Stage III Ovarian Cancer: A Therapy Whose Time Has Come. J Clin Oncol 20:3944-3946, 2002.

Armstrong DK. Relapsed Ovarian Cancer: Challenges and Management Strategies for a Chronic Disease. Oncologist; 7(Suppl 5):20-28, 2002.

Armstrong DK. Novel Therapies in Ovarian Cancer Management: An Update on the Role of Topotecan. Oncologist; 7(Suppl 5):1-2, 2002.

Bristow RE, Gossett DR, Shook DR, Zahurak ML, Tomacruz RS, Armstrong DK and Montz FJ. Micropapillary serous ovarian carcinoma: surgical management and clinical outcome. Gynecol Oncol. 86(2):163-70, 2002.

Emens LA, Kennedy MJ, Fetting JH, Davidson NE, Elza-Brown K, Armstrong DK. A phase I toxicity and feasibility trial of sequential dose dense induction chemotherapy with doxorubicin, paclitaxel, and 5-fluorouracil followed by high dose consolidation for high risk primary breast cancer. Breast Cancer Research and Treatment 76: 145-156, 2002.

Bristow RE, Gossett DR, Shook DR, Zahurak ML, Tomacruz RS, Armstrong DK, Montz FJ. Recurrent micropapillary serous ovarian carcinoma. Cancer. 95(4):791-800, 2002.

Armstrong DK, Blessing JA, Rader J and Sorosky JI. A randomized Phase II evaluation of bryostatin-1 (NSC#339555) in persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. (In Press)

Armstrong DK, Blessing JA, Look KY, Schilder R and Nunez ER. A randomized Phase II evaluation of bryostatin-1 (NSC#339555) in persistent or recurrent platinum-sensitive ovarian cancer: a Gynecologic Oncology Group study. (In Press)

DK Armstrong, BN Bundy, R Baergen, SB Lele, LJ Copeland, J Walker, R Burger. Randomized Phase III Study of Intravenous (IV) Paclitaxel and Cisplatin Versus IV Paclitaxel, Intraperitoneal (IP) Cisplatin and IP Paclitaxel in Optimal Stage III Epithelial Ovarian Cancer (OC): A Gynecologic Oncology Group Trial (GOG 172). Abstract # 803, Proc ASCO, 2002.

Robert E. Bristow, M.D.

Bristow RE, Zahurak ML, del Carmen MG, Gordon, Fox, HE, Trimble EL,Montz FJ. Ovarian Cancer Surgery in Maryland: Volume-Based Access to Care. Gynecologic Oncology 2004; 93: 353-360.

Bristow RE, del Carmen MG, Kaufman HS, Montz FJ. Radical oophorectomy with primary stapled colorectal anastomosis for resection of locally advanced epithelial ovarian cancer. J Am Coll Surg 2003; 197: 565-574.

Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival impact of maximum cytoreductive surgery for advanced ovarian carcinoma during the platinum-era: A meta-analysis. J Clin Oncol 2002; 20: 1248-1259.

Bristow RE, Montz FJ, Lagasse LD, Leuchter RS, Karlan BY. Survival impact of Surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol Oncol 1999;72: 278-287.

Bristow RE, Smith Sehdev AE, Kaufman HS, Kurman RJ, Montz FJ. Ablation of metastatic ovarian carcinoma with the argon beam coagulator: Pathologic analysis of tumor destruction. Gynecol Oncol 2001; 83: 49-55.

Bristow RE and Montz FJ. Complete surgical cytoreduction of advanced ovarian carcinoma using the argon beam coagulator. Gynecol Oncol 2001: 83: 39-48.

Bristow RE, del Carmen MG, Pannu HK, Cohade C, Zahurak MZ, Fishman EK,Wahl RL, Montz FJ. Clinically occult recurrent ovarian cancer: Patient selection for secondary cytoreductive surgery using combined PET/CT. Gynecol Oncol 2003;90: 519-528.

Bristow RE, Simpkins F, Pannu HK, Fishman EK, Montz FJ. Positron Emission Tomography (PET) for Detecting Clinically Occult Surgically Resectable Metastatic Ovarian Carcinoma. Gynecol Oncol 2002; 85: 196-200.

Bristow RE, Duska LR, Lambrou NC, Fishman EK, O’Neill MJ, Trimble EL,Montz FJ. A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography. Cancer 2000; 89: 1532-1540.

Pannu HK, Bristow RE, Cohade C, Fishman EK, Wahl RL. Multidetector CT of peritoneal carcinomatosis from ovarian cancer. Radiographics 2003; 23: 687-701.555-556.

Pannu HK, Bristow RE, Cohade C, Fishman EK, Wahl RL. PET-CT in recurrent ovarian cancer: initial observations. Radiographics 2004; 24: 209-223.

Pannu HK, Cohade C, Bristow RE, Fishman EK, Wahl RL. PET/CT detection of abdominal recurrence of ovarian cancer: radiologic – surgical correlation. Abdominal Imaging 2004; 39: 398-403.

Bristow RE, Gossett DR, Shook DR, Zahurak ML, Tomacruz RS, Armstrong DK,Montz FJ. Micropapillary serous ovarian carcinoma: surgical management and clinical outcome. Gynecol Oncol 2002; 86: 163-170.

Bristow RE, Gossett DR, Shook DR, Zahurak ML, Tomacruz RS, Armstrong DK, Montz FJ. Recurrent micropapillary serous ovarian carcinoma: the role of secondary cytoreductive surgery. Cancer 2002; 95: 791-800.

Bristow RE, Zahurak ML, Alexander CJ, Zellars RC, Montz FJ. FIGO Stage IIIC Endometrial carcinoma: Resection of macroscopic nodal disease and other determinants of survival. Int J Gynecol Cancer 2003; 13: 664-672.

Bristow RE, Lagasse LD, Karlan BY: Secondary surgical cytoreduction for advanced
epithelial ovarian cancer: Patient selection criteria and review of the literature. Cancer 1996; 78: 2049-2062.

Bristow RE, Zerbe MJ, Rosenshein NB, Grumbine FC, Montz FJ. Stage IVB Endometrial carcinoma: the role of cytoreductive surgery and determinants of survival. Gynecol Oncol 2000; 78: 85-91.

Bristow RE, Duska LR, Montz FJ. The role of cytoreductive surgery in the management of Stage IV uterine papillary serous carcinoma. Gynecol Oncol 2001;81: 92-99.

Bristow RE and Karlan BY: Ovulation induction, infertility, and ovarian cancer risk.
Fertil Steril 1996; 66: 499-507

Bristow RE, Asrari F, Trimble EL, Montz FJ. Extended surgical staging for uterine papillary serous carcinoma: Survival outcome of Loco-Regional (Stage I-III) disease. Gynecol Oncol 2001; 81: 279-286.

Montz FJ, Bristow RE, Bovicelli A, Tomacruz R, Kurman RJ. Intrauterine progesterone treatment of early endometrial cancer. Am J Obstet Gynecol 2002; 186:651-647.

Pannu HK, Bristow RE, Montz FJ, Fishman EK. Dual phase multidetector computed tomography with volume display in gynecologic cancers. In press, J Women’s Imaging.

Wolfberg A, Montz FJ, Bristow RE. The role obesity in the surgical management of advanced stage ovarian cancer. J Reprod Med 2004; 49: 473-476.

Richard Roden, Ph.D.

Yang, R, and RBS Roden. Genetic polymorphism and Tumor Immunotherapy. Current Pharmacogenomics 2003; 1, 37-57.

Yang, R, Yutzy, WH, Lin, K, Hung, C-F, and RBS Roden. A cell surface binding motif of L2 facilitates papillomavirus infection. J. Virol 2003 Mar;77(6):3531-41.

Yang, R, Yutzy, WH, Viscidi, R, and RBS Roden. Interaction of L2 with ƒÒ-actin facilitates intracellular transport of papillomavirus and infection. J Biol Chem. 2003 Apr 4;278(14):12546-53.

Wang, BG, Hwang H-Y, Chen, Y-C, Bristow, RE, Cheng, K, Roden, RBS, Chen, DW, and I-M Shih. Increased plasma DNA integrity in cancer patients. Cancer Res. 2003 Jul 15;63(14):3966-8.

Roden, RBS and T-C Wu. Preventive and Therapeutic Vaccines for Cervical Cancer. Expert Rev. Vaccines 2003 2(4): 89-110.

Ie-Ming Shih, M.D.

Singer G, Shih IM, Truskinovsky A, Umudum H, Kurman RJ. Mutational analysis of K-ras segregates ovarian serous carcinomas into two types: Invasive MPSC (a low-grade tumor) and conventional serous carcinoma (a high-grade tumor). Int J Gynecol Pathol, 22:37-41, 2003.

Singer G, Oldt 3rd R, Cohen Y, Wang B, Sidransky D, Kurman RJ, Shih IM. Mutations in BRAF and KRAS Ras characterize the development of low-grade ovarian serous carcinoma. J Natl Can Inst, 95:484-486, 2003.

Pires FR, Shih IM, Perez DE, Almeida OP, Kowalski LP. Mel-CAM (CD146) expression in parotid mucoepidermoid carcinoma. Oral Oncol 39:277-281, 2003.

Buckhaults P, Zhang Z, Chen Y-C, Wang T-L, St. Croix B, Saha S, Bardelli A, Morin PJ, Polyak K, Hruban RH, Velculescu VE, Shih IM. Identifying tumor origin using a gene expression based classification map. Cancer Res, 63:4144-4149, 2003 (with cover illustration).

Wang BG, Huang H-Y, Chen Y-C, Bristow RE, Kassauei K, Cheng C-C, Roden R, Sokoll LJ, Chan DW, Shih I-M. Increased plasma DNA integrity in cancer patients. Cancer Res, 63:3966-3968, 2003.

T.-C. Wu, M.D., Ph.D.

Cheng, W. F., Hung, C. F., Chai, C. Y., Hsu, K. F., He, L., Ling, M., and Wu, T. C. (2001). Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. J Clin Invest 108, 669-678.

Cheng, W. F., Hung, C. F., Hsu, K. F., Chai, C. Y., He, L., Polo, J. M., Slater, L. A., Ling, M., and Wu, T. C. (2002). Cancer Immunotherapy Using Sindbis Virus Replicon Particles Encoding a VP22--Antigen Fusion. Hum Gene Ther 13, 553-568.

Hung, C. F., He, L., Juang, J., Lin, T. J., Ling, M., and Wu, T. C. (2002). Improving DNA vaccine potency by linking Marek's disease virus type 1 VP22 to an antigen. J Virol 76, 2676-2682.

T. W. Kim, C.-F. Hung, M. Ling, J. Juang, L. He, J. M. Hardwick, S. Kumar, and T.-C. Wu (2003) Enhancing DNA vaccine potency by co-administration of DNA encoding anti-apoptotic proteins. J. Clin. Invest. 112: 109-117.